Las Vegas, NV -- (SBWIRE) -- 10/25/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is on: Zhone Technologies Inc (NASDAQ:ZHNE), Horizon Pharma Inc (NASDAQ:HZNP), Citigroup Inc (NYSE:C), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Zhone Technologies Inc (NASDAQ:ZHNE) managed to keep its gain at 7.78% on above-normal volume of 1.54M shares. The stock settled at $4.14 after floating in a range of $3.80 to $4.32. Its latest price has reached market capitalization of $3.85 million. Its 52-week range has been $0.40 to $4.58. Zhone Technologies Inc. (Zhone) designs, develops and manufactures communications networks equipment for telecommunications, wireless and cable operators worldwide. With the Company's products and solutions.
For How Long ZHNE will fight for Profitability? Read This Trend Analysis report
Horizon Pharma Inc (NASDAQ:HZNP) traded up on a volume of 1.51 million, higher than its standard daily volume. Shares have gained 5.50% to $4.60. Over the last twelve months, the stock has gained 47.44% and faced a worst price of $1.97. Horizon Pharma, Inc. operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
For How Long HZNP’s Gloss will Attract Investors? Find out via this report
Citigroup Inc (NYSE:C) settled -0.08% lower at $50.15 on below -normal volume of 20.04M shares during the last trading day. The stock has its 12-month high at $53.56 and 52-week low price was $34.04. It traded in a range of $49.77 to $50.31 during the last trading day. Citigroup Inc. (Citigroup) is a global diversified financial services holding company whose businesses provide consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services and wealth management.
Will C sGet Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was down on low volume, trading at a volume of 1.50M shares versus its average daily volume of 4.27 million shares. At $2.61, the stock has attained market capitalization of $252.24 million. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections.
Why Should Investors Buy ACHN After the Recent Fall? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)